Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line commercial communications to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

News

Menarini chooses Google Cloud for its digital transformation
The Menarini Group, a worldwide leader in the pharmaceutical industry, has chosen Google Cloud to help it work in a smarter and more flexible way, through the use of G Suite which will allow its 17,000 employees to work...
Menarini Ricerche to present the most recent pre-clinical data about the PI3K inhibitor MEN1611 at the AACR Annual Meeting 2018.
Menarini Ricerche  will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in development for solid tumors, at the AACR Annual Meeting 2018, which will take pla...
MENARINI ANNOUNCES NEW GOVERNANCE
Pharmaceutical group Menarini, headed by the Aleotti family, has decided to entrust the  Chairmanship of the company  to an external manager coming from a large multinational,  Dr. Eric Cornut.  The new chairmanship will...
Menarini hires their 17,000th employee
The  17,000 th  employee in Menarini is Lara, 28 years old, a young graduate in Chemistry and Pharmaceutical Technology from the University of Florence, who is now employed in  Menarini Ricerche.
The Menarini Group announced marketing authorization Application for delafloxacin
The Menarini Group announced today that on March 6th 2017 it has submitted a Marketing Authorization Application for delafloxacin at the European Medicines Agency (EMA) under the trade name Quofenix. The proposed indication ...
Page 1 of 3First   Previous   [1]  2  3  Next   Last   

Quality first

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »